Acoustic ejection mass spectrometry empowers ultra-fast protein biomarker quantification
Bart Van Puyvelde, Christie L. Hunter, Maxim Zhgamadze, Sudha S. Savant, Y. Wang, Esthelle Hoedt, Koen Raedschelders, Matt Pope, Carissa A. Huynh, V. Krishnan Ramanujan, Warren G. Tourtellotte, Morteza Razavi, N. Leigh Anderson, Geert A. Martens, Dieter Deforce, Qin Fu, Maarten Dhaenens, Jennifer E. Van Eyk
Abstract
The global scientific response to COVID 19 highlighted the urgent need for increased throughput and capacity in bioanalytical laboratories, especially for the precise quantification of proteins that pertain to health and disease. Acoustic ejection mass spectrometry (AEMS) represents a much-needed paradigm shift for ultra-fast biomarker screening. Here, a quantitative AEMS assays is presented, employing peptide immunocapture to enrich (i) 10 acute phase response (APR) protein markers from plasma, and (ii) SARS-CoV-2 NCAP peptides from nasopharyngeal swabs. The APR proteins were quantified in 267 plasma samples, in triplicate in 4.8 h, with %CV from 4.2% to 10.5%. SARS-CoV-2 peptides were quantified in triplicate from 145 viral swabs in 10 min. This assay represents a 15-fold speed improvement over LC-MS, with instrument stability demonstrated across 10,000 peptide measurements. The combination of speed from AEMS and selectivity from peptide immunocapture enables ultra-high throughput, reproducible quantitative biomarker screening in very large cohorts.